Cai Qin-Yu, Tang Wei-Zhen, Li Zhi-Mou, Li Jia-Zheng, Zhi Xing-Qi, Yang Qin-Hao, Sheng Jie, Liu Tai-Hang
Department of Bioinformatics, School of Basic Medical Sciences, Chongqing Medical University, Chongqing, China.
The Joint International Research Laboratory of Reproduction and Development, Chongqing Medical University, Chongqing, China.
Cell Death Discov. 2025 Oct 16;11(1):461. doi: 10.1038/s41420-025-02753-w.
Recurrent implantation failure (RIF) poses a significant challenge in treating infertility. RIF can stem from various factors, commonly involving immune issues. Recent literature suggests that glucocorticoids (GCs) can effectively inhibit immune responses in RIF patients. However, a recent multicenter randomized controlled trial found that oral prednisone did not enhance live birth rates in RIF cases. Despite their potential benefits, the diversity in dosage regimens and treatment protocols highlights the need for further research to establish standardized guidelines and ensure long-term safety. This review explores the use of GCs treatments for RIF, including their use alone and in combination with other medications. It emphasizes the necessity for solid evidence to determine the effectiveness and safety of these treatments. Future studies should focus on defining optimal dosages, treatment durations, and administration methods tailored to different RIF patient profiles. Moreover, well-designed randomized trials are crucial to assess the efficacy and risks associated with GCs in treating RIF.
反复种植失败（RIF）给不孕症治疗带来了重大挑战。RIF可能源于多种因素，通常涉及免疫问题。近期文献表明，糖皮质激素（GCs）可有效抑制RIF患者的免疫反应。然而，最近一项多中心随机对照试验发现，口服泼尼松并不能提高RIF病例的活产率。尽管GCs有潜在益处，但给药方案和治疗方案的多样性凸显了进一步研究以建立标准化指南并确保长期安全性的必要性。本综述探讨了GCs治疗RIF的应用，包括单独使用及其与其他药物联合使用的情况。强调了要有确凿证据来确定这些治疗的有效性和安全性。未来的研究应侧重于确定针对不同RIF患者特征的最佳剂量、治疗持续时间和给药方法。此外，精心设计的随机试验对于评估GCs治疗RIF的疗效和风险至关重要。
